TD Cowen analyst Daniel Brennan maintains $Bruker Corp (BRKR.US)$ with a hold rating, and maintains the target price at $70.
According to TipRanks data, the analyst has a success rate of 50.8% and a total average return of 14.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Bruker Corp (BRKR.US)$'s main analysts recently are as follows:
Post the Q3 report, Bruker experienced continued softness in the China market and in the biopharma sector.
The company faced a challenging reporting period within a difficult macroeconomic situation. Estimates are being adjusted to align with the reduced fiscal 2024 targets. Nevertheless, there is confidence that the company's strong positioning in multi-omics and materials sciences will enable it to capitalize on the anticipated demand resurgence in the biopharma sector and the Chinese market.
Bruker's third-quarter results fell short of expectations, and the company revised its organic sales growth forecast for fiscal 2024 downwards, attributing the slower pace to a delayed resurgence in China and emerging biopharma sectors. Analysts have pointed out that the adjustment in guidance was not a result of a significant market downturn in the third quarter, but was instead due to previous forecasts being too optimistic. Despite this, management has expressed a confident outlook for 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Daniel Brennan維持$布魯克 (BRKR.US)$持有評級，維持目標價70美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.8%，總平均回報率為14.4%。
此外，綜合報道，$布魯克 (BRKR.US)$近期主要分析師觀點如下：
發帖Q3報告後，Bruker在中國市場和生物製藥板塊繼續面臨疲軟局面。
公司在困難的宏觀經濟環境中度過了具有挑戰性的報告期。 估計正在調整以符合減少的2024財年目標。 儘管如此，公司強調多組學和材料科學領域的強勁定位將使其能夠充分利用生物製藥領域和中國市場預期需求復甦的機會。
Bruker第三季度業績低於預期，並調低了2024財年有機銷售增長預測，原因是中國和新興生物製藥行業復甦延遲。 分析師指出，指導方針的調整不是第三季度市場顯著下滑的結果，而是由於先前的預測過於樂觀。 儘管如此，管理層對2025年表示信心滿滿。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
